Share ownership Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 06/03/2026 am IST			5-day change	1st Jan Change
143.57 ^USD	-4.21%		-4.29%	-17.51%

02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
24/02	Insmed Insider Sold Shares Worth $1,615,257, According to a Recent SEC Filing	MT

Share class: Insmed Incorporated

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,89,02,721	17,70,91,433 ( 98.99 %)	0	98.99 %

Major shareholders: Insmed Incorporated

Name	Equities	%	Valuation
JPMorgan Investment Management, Inc. 10.88 %	2,31,99,512	10.88 %	3 639 M $
Vanguard Fiduciary Trust Co. 9.882 %	2,10,76,344	9.882 %	3 306 M $
Darwin Global Management Ltd. 9.815 %	2,09,33,277	9.815 %	3 284 M $
BlackRock Advisors LLC 6.02 %	1,28,39,122	6.02 %	2 014 M $
Fidelity Management & Research Co. LLC 4.655 %	99,27,333	4.655 %	1 557 M $
Baker Bros. Advisors LP 3.091 %	65,92,746	3.091 %	1 034 M $
STATE STREET CORPORATION 2.439 %	52,01,744	2.439 %	816 M $
Capital Research & Management Co. (International Investors) 2.416 %	51,51,671	2.416 %	808 M $
Artisan Partners Holdings LP 2.271 %	48,43,749	2.271 %	760 M $
RTW Investments LP 2.271 %	48,42,879	2.271 %	760 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	84.73%
Other	12%
State Street Corp.	2.44%
Individuals	0.84%
SEI Investments Co.	0.46%
Schweizerische Nationalbank	0.27%
Sumitomo Mitsui Trust Group, Inc.	0.2%
Polar Capital Holdings Plc	0.16%
Governments	0.14%
Zurich Insurance Group AG	0.13%
ING Groep NV	0.06%
Manulife Financial Corp.	0.06%
Skandinaviska Enskilda Banken AB	0.05%
Danske Bank A/S	0.05%
The Bank of Nova Scotia	0.03%
Swedbank AB	0.03%
The Allstate Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	76.18%
United Kingdom	15.95%
Bermuda	1.96%
Norway	1.46%
Switzerland	0.97%
Japan	0.97%
Individuals	0.84%
Canada	0.62%
Sweden	0.51%
Germany	0.4%
Ireland	0.28%
Denmark	0.27%
Luxembourg	0.25%
Australia	0.22%
France	0.19%
South Korea	0.17%
Netherlands	0.07%
Puerto Rico	0.07%
Cayman Islands	0.06%
Hong Kong	0.05%
China	0.05%
Austria	0.03%
Belgium	0.02%
Taiwan	0.02%
Poland	0.01%
Singapore	0.01%
Finland	0.01%
Italy	0.01%
India	0.01%

Based on 1000 largest holdings

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,664

Sector

Biotechnology & Medical Research

More about the company